Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference
01 Giugno 2023 - 1:57PM
Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the
“Company”), a biotechnology company focused on the discovery,
research, and development of innovative treatments for central
nervous system (CNS) disorders, today announced that pre-clinical
results for its lead drug candidate, PAS-004, have been accepted
for a poster presentation at the 2023 Neurofibromatosis (NF)
Conference taking place June 24-27, 2023, in Scottsdale, Arizona.
“We are extremely pleased to be presenting
preclinical data from PAS-004 conducted in collaboration with Dr.
Wade Clapp at Indiana University, School of Medicine,” commented
Dr. Graeme Currie, Pasithea’s Chief Development Officer. “The
presentation will provide insight into PAS-004 efficacy and support
further development of our lead candidate.”
Findings will be shared on a poster entitled
“Evaluation of the Effects of a Novel MEK inhibitor PAS-004 in
Plexiform Neurofibroma in a Pre-clinical Mouse Model of
Neurofibromatosis Type 1”. Poster will be available to view during
the 2023 NF Conference on the evening of Sunday, June 25th, from
5:00pm - 7:00pm.
About NF conference
First held in 1985 as a roundtable of 20
participants, the NF Conference is now the most important scholarly
gathering of the NF research and clinical communities. The NF
Conference is a global event organized by Children's Tumor
Foundation (CTF), now attracting nearly 750 participants worldwide
across a wide range of scientific disciplines, from research and
clinical backgrounds, all focused on improving outcomes for
patients with neurofibromatosis type 1 (NF1), neurofibromatosis
type 2 (NF2) and schwannomatosis. The NF Conference is a critical
forum for consensus building and advancing basic, translational,
and clinical research in NF and related fields, while fostering
collaborations within and beyond the NF community. Importantly, the
NF Conference is a key venue for attracting and growing new
investigators in NF research and clinical care.
About PAS-004
PAS-004 is a small molecule allosteric inhibitor
of MEK 1/2 in the MAPK signaling pathway. The MAPK pathway has been
implicated in a variety of diseases, as it functions to drive cell
proliferation, differentiation, survival and a variety of other
cellular functions that, when abnormally activated, are critical
for the formation and progression of tumors, fibrosis and other
diseases. MEK inhibitors block phosphorylation (activation) of
extracellular signal-regulated kinases (ERK). Blocking the
phosphorylation of ERK can lead to cell death and inhibition of
tumor growth. Existing FDA approved MEK inhibitors are marketed for
a range of diseases, including certain cancers and NF1. We believe
these MEK inhibitors suffer from certain limitations, including
known toxicities. Unlike current FDA approved MEK inhibitors,
PAS-004 is macrocyclic, which we believe may lead to improved
pharmacokinetic and safety (tolerability) profiles. Cyclization
offers rigidity for stronger binding with drug target receptors.
PAS-004 was designed to provide a longer half-life with what we
believe is a better therapeutic window. Further, we believe the
potency and safety profile that PAS-004 has demonstrated in
preclinical studies may also lead to stronger and more durable
response rates and efficacy, as well as better dosing schedules,
which may not require the fasting or dietary restrictions of
approved MEK inhibitors. PAS-004 has been tested in a range of
mouse models of various diseases and has completed preclinical
testing and animal toxicology studies to support an IND application
with the FDA that we plan to submit in the third quarter of 2023.
Additionally, PAS-004 has received orphan-drug designation from the
FDA for the treatment of NF1.
About Pasithea
Therapeutics Corp.
Pasithea Therapeutics
is a biotechnology company primarily focused on the discovery,
research and development of innovative treatments for central
nervous system (CNS) disorders and RASopathies. With an experienced
team of experts in the fields of neuroscience, translational
medicine, and drug development, Pasithea is developing new
molecular entities for the treatment of neurological disorders,
including Neurofibromatosis type 1 (NF1), Amyotrophic Lateral
Sclerosis (ALS) and Multiple Sclerosis (MS).
Forward
Looking Statements
This press release
contains statements that constitute “forward-looking statements.”
Forward-looking statements are subject to numerous conditions, many
of which are beyond the control of the Company. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to the Company
on the date of this release. These forward-looking statements are
based upon current estimates and assumptions and are subject to
various risks and uncertainties, including, without limitation,
those set forth in the Company’s filings with the U.S. Securities
and Exchange Commission (SEC). Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
ContactPatrick GaynesCorporate
Communicationspgaynes@pasithea.com
Grafico Azioni Pasithea Therapeutics (NASDAQ:KTTAW)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Pasithea Therapeutics (NASDAQ:KTTAW)
Storico
Da Set 2023 a Set 2024